Healthleap, a clinical artificial intelligence company founded in South Africa, has raised $38mn in combined seed and Series A funding, as investors bet that software capable of surfacing undiagnosed conditions from hospital records can both improve patient care and generate measurable financial returns for health systems.
The financing comprises an $8mn seed round co-led by Sequoia Capital and First Round Capital, and a $30mn Series A led by Hummingbird Ventures. The company declined to disclose its valuation.
Founded in 2022 by siblings Jemima and Josiah Meyer, Healthleap began as a clinical nutrition tool that Jemima, a dietitian, built to help colleagues identify and treat malnourished patients sooner. The company later pivoted to a broader platform that ingests electronic health record (EHR) data and uses language models to flag adult inpatients who may warrant closer clinical attention. The company has since but relocated and headquartered in San Francisco, United States.
The platform’s core premise is that much of the most diagnostically useful information in a patient’s chart is buried in free-text clinician notes — references to poor appetite, recent weight loss, muscle wasting or difficulty swallowing — rather than in structured fields such as laboratory results and vital signs. Healthleap’s software analyses both categories overnight, then writes a risk score into the care team’s existing workflow each morning. The company is explicit that its tool does not diagnose patients; it only highlights individuals for additional review.
Healthleap’s initial commercial focus, disease-related malnutrition, illustrates the scale of the diagnostic gap it is targeting. Up to half of hospitalised patients are considered at risk of malnutrition, yet fewer than 9 per cent receive a formal diagnosis, according to figures cited by the company and reported by Fierce Healthcare. Conventional screening often relies on a brief nurse-administered questionnaire at admission, which can miss patients who are sedated, confused or too ill to respond. Malnutrition is associated with longer hospital stays, impaired wound healing, higher infection rates and increased mortality, making early identification clinically and economically consequential.
The financial logic of Healthleap’s proposition rests on two levers that matter acutely to US hospital finance teams: appropriate reimbursement and avoided costs. Accurate documentation of severe malnutrition can qualify a hospital for additional payment per eligible encounter, while shorter lengths of stay reduce the fixed and variable costs of inpatient care. Healthleap says its malnutrition programme at one Penn Medicine hospital generated an estimated $23.8mn in annualised financial impact, comprising $6.3mn in additional reimbursement and $17.5mn from reduced lengths of stay. Across enterprise deployments, the company reports a 39 per cent increase in identified and treated malnutrition cases and $11mn in incremental reimbursement within one health system.
Those figures are company-reported and have not been independently audited in public filings. But they point to a broader trend in US healthcare: hospitals facing pressure from Medicare’s Hospital Readmissions Reduction Program, which can penalise reimbursements by up to 3 per cent for excess readmissions, are increasingly willing to pay for tools that promise to catch complications earlier. Healthleap says every customer has achieved at least a 5x hard return on investment, and in some cases more than 20x, though it did not disclose the underlying calculations or contract values. The company sells three-year contracts priced on licensed bed count, with an outcome-based component tied to finance-team-validated savings.
Healthleap’s expansion into delirium follows a similar rationale. Delirium affects one-third of hospitalised older adults and is associated with prolonged stays, functional decline and death; its annual US cost burden exceeds $182bn, according to research published in JAMA Internal Medicine. Yet more than half of delirium cases go unrecognised in routine care. The company has also built programmes for aspiration pneumonia, pressure ulcers and readmission risk in congestive heart failure, which it says are undergoing further clinical validation.
The technology sits in a sensitive regulatory space. Clinical decision support software that informs, but does not replace, clinician judgment can fall outside the US Food and Drug Administration’s device framework under certain statutory criteria, while tools that make independent diagnostic claims face stricter oversight as software as a medical device. Healthleap’s positioning as a screening and triage aid, rather than a diagnostic product, is designed to navigate that distinction, but hospitals deploying such systems must still ensure that alerts are clinically meaningful and do not simply generate additional administrative burden.
Healthleap’s customer base has expanded from three hospital partners a year ago to more than 50, including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Revenue has grown more than 10-fold over the same period, according to the company, though specific figures were not disclosed. The fresh capital will be used for engineering, product, sales and customer success, as Healthleap seeks to extend coverage to more than 40 major conditions and expand beyond inpatient settings into outpatient and home care.
For Sequoia and First Round, the seed investment reflects a familiar thesis: that AI applied to messy, unstructured clinical data can unlock value where rule-based systems and manual screening have fallen short. “We were immediately drawn to Healthleap’s bold vision: imagine if every hospital could use real-time AI to spot overlooked clinical risk, improve patient care, and unlock meaningful reimbursement revenue,” said Josh Kopelman, co-founder and partner at First Round Capital. Hummingbird Ventures led the Series A, signalling continued investor appetite for healthcare AI companies that can demonstrate near-term financial returns rather than speculative long-term disruption.
The central question for Healthleap is whether its early results can be replicated across a customer base that spans different EHR systems, coding practices and clinical workflows. The company’s growth from a single nutrition tool built by a practising dietitian to a multi-condition screening platform in four years is notable. But the hard test will be whether hospitals beyond the flagship Penn Medicine deployment can achieve comparable returns — and whether clinicians will trust, rather than tune out, another stream of automated alerts.